Dr. Abou-Alfa on Efficacy With Ivosidenib in IDH1+ Cholangiocarcinoma

Video

Ghassan K. Abou-Alfa, MD, discusses the efficacy of ivosidenib in IDH1-mutant cholangiocarcinoma based on the results of the phase 3 ClarIDHy study.

Ghassan K. Abou-Alfa, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the efficacy of Ivosidenib (Tibsovo) in IDH1-mutant cholangiocarcinoma based on the results of the phase 3 ClarIDHy study (NCT02989857).

The results of the study were positive, based on a primary end point of progression-free survival (PFS), which demonstrated clear disease suppression at 6 months and 12 months, Abou-Alfa says. Notably, 70% patients from the placebo arm crossed over to receive ivosidenib with a clear improvement in survival.

Patients on the ivosidinib arm experienced a significant improvement in median overall survival (OS) of up to 10.3 months, while patients on the placebo arm who did not crossover had a rank-preserving structural failure time–adjusted OS of 5.1 months, Abou-Alfa says. This translated to a doubling of survival, which is not ordinarily observed in cholangiocarcinoma, he says.

Additionally, the adverse effects associated with the agent were limited and quality of life was also in favor of ivosidenib, Abou-Alfa explains. Having wide availability of ivosidenib for patients with cholangiocarcinoma would be an exciting prospect, Abou-Alfa concludes.

Related Videos
Patrick I. Borgen, MD
Kari Hacker, MD, PhD, NYU Grossman School of Medicine
Janos L. Tanyi, MD, PhD, associate professor, Obstetrics and Gynecology, Hospital of the University of Pennsylvania
Reshma Lillaney Mahtani, DO
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center